Literature DB >> 15729608

Value of a standard urinary dipstick test for detecting microalbuminuria in patients with newly diagnosed hypertension.

Andreas Zeller1, Jörg-Peter Sigle, Edouard Battegay, Benedict Martina.   

Abstract

PRINCIPLES: Microalbuminuria may indicate target organ damage in hypertensive patients. However, testing for microalbuminuria is not yet consistently used in general practice. This may be partly due to a lack of data regarding the diagnostic value of practice-based dipstick testing in newly diagnosed hypertension. Objectives were to assess the diagnostic value of a standard dipstick test for urinary protein excretion.
METHOD: 186 patients who had been newly diagnosed with hypertension were screened for microalbuminuria. A spot urine sample from each of the subjects was evaluated by using a standard dipstick test (Combur 10, Roche Diagnostics GmbH, Mannheim, Germany) in a primary care setting. The albumin/creatinine ratio was used as the "gold standard".
RESULTS: Dipstick testing for protein was positive in 31 urine samples (16.7% of the test samples). The albumin/creatinine ratio was elevated in 33 samples (17.7% of the test samples). The sensitivity of detecting microalbuminuria was 26%, specificity 89%, positive predictive value 45%, and the negative predictive was 88%. Repeated dipstick testing 48 hours after the initial testing in 40 randomly selected patients showed a good reproducibility (98%).
CONCLUSIONS: In a primary care setting a positive standard dipstick test of a random spot urine in patients with newly diagnosed hypertension may indicate the presence of microalbuminuria with high specificity. However, because of its low sensitivity, the standard urinary dipstick test can not be recommended as the sole method of screening for renal target organ damage. In addition standard dipstick testing is important to exclude confounding factors that can falsify the measurement of urinary protein excretion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15729608     DOI: 2005/03/smw-10859

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  7 in total

1.  Clinical utility of trace proteinuria for microalbuminuria screening in the general population.

Authors:  Tsuneo Konta; Zhimei Hao; Satoshi Takasaki; Hiroshi Abiko; Mizue Ishikawa; Toshiyuki Takahashi; Ami Ikeda; Kazunobu Ichikawa; Takeo Kato; Sumio Kawata; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

2.  Occult chronic kidney disease among persons with hypertension in the United States: data from the National Health and Nutrition Surveys 1988-1994 and 1999-2002.

Authors:  Carmen A Peralta; Cristin C Weekley; Yongmei Li; Michael G Shlipak
Journal:  J Hypertens       Date:  2013-06       Impact factor: 4.844

3.  Prevalence of microalbuminuria and diagnostic value of dipstick proteinuria in outpatients from HIV clinics in Bukavu, the Democratic Republic of Congo.

Authors:  Mannix Imani Masimango; Ernest Kiswaya Sumaili; Michel Jadoul; Pierre Wallemacq; Dieudonné Kanigula Mubagwa; Rissassy Jean-Robert Makulo; François Bompeka Lepira; Nazaire Mangani Nseka
Journal:  BMC Nephrol       Date:  2014-09-05       Impact factor: 2.388

4.  Burden of Hypertension and Abnormal Glomerular Permeability in Hypertensive School Children.

Authors:  Adebukola B Ajite; Theophilus A Aladekomo; Temilade Aderounmu; Wasiu A Olowu
Journal:  Nephrourol Mon       Date:  2016-05-21

5.  Comparison of Two Different Semiquantitative Urinary Dipstick Tests with Albumin-to-Creatinine Ratio for Screening and Classification of Albuminuria According to KDIGO. A Diagnostic Test Study.

Authors:  Nikolai C Hodel; Ali Hamad; Klaus Reither; Irene Mndala Kasella; Salim Abdulla; Andreas Schoetzau; Christoph F R Hatz; Michael Mayr
Journal:  Diagnostics (Basel)       Date:  2021-01-06

6.  The coArtHA trial-identifying the most effective treatment strategies to control arterial hypertension in sub-Saharan Africa: study protocol for a randomized controlled trial.

Authors:  Thilo Burkard; Maja Weisser; Herry Mapesi; Ravi Gupta; Herieth Ismael Wilson; Blaise Lukau; Alain Amstutz; Aza Lyimo; Josephine Muhairwe; Elizabeth Senkoro; Theonestina Byakuzana; Madavida Mphunyane; Moniek Bresser; Tracy Renée Glass; Mark Lambiris; Günther Fink; Winfrid Gingo; Manuel Battegay; Daniel Henry Paris; Martin Rohacek; Fiona Vanobberghen; Niklaus Daniel Labhardt
Journal:  Trials       Date:  2021-01-21       Impact factor: 2.279

7.  Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol.

Authors:  Lutgarde Thijs; Kei Asayama; Gladys E Maestre; Tine W Hansen; Luk Buyse; Dong-Mei Wei; Jesus D Melgarejo; Jana Brguljan-Hitij; Hao-Min Cheng; Fabio de Souza; Natasza Gilis-Malinowska; Kalina Kawecka-Jaszcz; Carina Mels; Gontse Mokwatsi; Elisabeth S Muxfeldt; Krzysztof Narkiewicz; Augustine N Odili; Marek Rajzer; Aletta E Schutte; Katarzyna Stolarz-Skrzypek; Yi-Wen Tsai; Thomas Vanassche; Raymond Vanholder; Zhen-Yu Zhang; Peter Verhamme; Ruan Kruger; Harald Mischak; Jan A Staessen
Journal:  Blood Press       Date:  2021-08-30       Impact factor: 1.771

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.